The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis

Author： Poole Chris D.   Tetlow Tony   McEwan Phil   Holmes Paul   Currie Craig J.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.23, Iss.1, 2007-02, pp. : 41-48

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis

By Currie Craig J.   Poole Chris D.   Tetlow Tony   Holmes Paul   McEwan Phil  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-02 ,pp. : 33-39

Informa Healthcare

Access to resources Recommend Favorite

Glucose‐lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 554-559

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK

By McEwan Phil   Poole Chris D.   Tetlow Tony   Holmes Paul   Currie Craig J.  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-02 ,pp. : 7-19

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK

By McEwan Phil   Poole Chris D.   Tetlow Tony   Holmes Paul   Currie Craig J.  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-02 ,pp. : 21-31

Informa Healthcare

Access to resources Recommend Favorite

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

By Valentine William J.   Palmer Andrew J.   Lammert Morten   Nicklasson Lars   Foos Volker   Roze Stéphane  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 2063-2071

Informa Healthcare

Access to resources Recommend Favorite